Pfizer Can't Shake Securities Action Over Celebrex Risks

Law360, New York (March 29, 2013, 5:23 PM ET) -- A New York federal judge on Thursday trimmed a long-running securities class action accusing Pfizer Inc. of concealing serious health risks associated with blockbuster painkillers Celebrex and Bextra, but ruled the bulk of the plaintiff's allegations were strong enough to advance.

U.S. District Judge Laura Taylor Swain whittled away some claims that were based on various news reports about deaths allegedly linked to the drugs because the causal connection was refuted by health officials. She also tossed allegations related to statements made by certain company officials...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers